Geode Capital Management LLC Increases Stock Holdings in Pfizer Inc. $PFE

Geode Capital Management LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 0.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 130,192,081 shares of the biopharmaceutical company’s stock after buying an additional 1,184,728 shares during the quarter. Geode Capital Management LLC’s holdings in Pfizer were worth $3,235,642,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PFE. Franklin Resources Inc. raised its holdings in Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after purchasing an additional 8,108,887 shares in the last quarter. Vanguard Group Inc. raised its holdings in Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. Neuberger Berman Group LLC raised its holdings in Pfizer by 203.8% in the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after purchasing an additional 6,045,763 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Pfizer by 48.2% in the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after purchasing an additional 5,978,927 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in Pfizer by 120.9% in the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock worth $230,986,000 after purchasing an additional 5,202,884 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced new late-stage trial activity for its infant pneumococcal vaccine and obesity drug berobenatide, reinforcing that the company is pushing to build future growth drivers beyond its aging portfolio. Pfizer’s Next-Gen Infant Pneumococcal Vaccine Trial: What Investors Should Watch Now
• Positive Sentiment: BofA Securities raised its price target on Pfizer to $27 from $26 after strong first-quarter results and improved 2026 revenue/EPS estimates, signaling continued analyst confidence in the stock’s valuation. BofA Raises Price Target on Pfizer (PFE) Following Strong Q1 Results
• Positive Sentiment: Pfizer is also highlighting its obesity push with a new Phase 3 trial, which could add another major opportunity if results are favorable. Pfizer Steps Up Obesity Push With New Phase 3 Berobenatide Trial
• Neutral Sentiment: Recent commentary says Pfizer is leaning on new launches, Seagen assets, and pipeline progress to offset looming loss-of-exclusivity pressure, but the patent cliff through 2030 remains a major overhang for investors. Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure?
• Negative Sentiment: Broader industry coverage on the Eliquis patent cliff underscores the kind of revenue loss Pfizer and peers can face when exclusivity ends, keeping attention on the company’s future replacement pipeline. Thinning revenues: inside the $14bn Eliquis patent cliff

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Citigroup raised their price target on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Finally, Bank of America reduced their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.61.

Pfizer Trading Up 1.5%

Shares of NYSE:PFE opened at $26.24 on Thursday. The stock has a market capitalization of $149.55 billion, a price-to-earnings ratio of 20.03 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock’s 50-day simple moving average is $26.82 and its two-hundred day simple moving average is $26.27. Pfizer Inc. has a 52-week low of $23.06 and a 52-week high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the firm earned $0.92 EPS. The business’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.